These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24864125)

  • 21. Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.
    Strengell M; Ikonen N; Ziegler T; Kantele A; Anttila VJ; Julkunen I
    Influenza Other Respir Viruses; 2013 May; 7(3):431-8. PubMed ID: 22913369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
    Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.
    Couch RB; Bayas JM; Caso C; Mbawuike IN; López CN; Claeys C; El Idrissi M; Hervé C; Laupèze B; Oostvogels L; Moris P
    BMC Infect Dis; 2014 Jul; 14():425. PubMed ID: 25078387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
    Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
    Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina M; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Health Technol Assess; 2010 Dec; 14(55):193-334. PubMed ID: 21208550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.
    Herrera MT; Gonzalez Y; Juárez E; Hernández-Sánchez F; Carranza C; Sarabia C; Guzman-Beltran S; Manjarrez ME; Muñoz-Torrico M; Garcia-Garcia L; Sada E; Torres M
    BMC Infect Dis; 2013 Nov; 13():544. PubMed ID: 24238117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
    Ferguson M; Risi G; Davis M; Sheldon E; Baron M; Li P; Madariaga M; Fries L; Godeaux O; Vaughn D
    J Infect Dis; 2012 Mar; 205(5):733-44. PubMed ID: 22315336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Gerber MA; Keyserling HL; Munoz FM; Winokur PL; Turley CB; Rupp RE; Hill H; Wolff M; Noah DL; Ross AC; Cress G; Belshe RB
    J Infect Dis; 2012 Sep; 206(6):828-37. PubMed ID: 22802432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
    Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
    Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
    Lambe T; Spencer AJ; Mullarkey CE; Antrobus RD; Yu LM; de Whalley P; Thompson BA; Jones C; Chalk J; Kerridge S; Hill AV; Snape MD; Pollard AJ; Gilbert SC
    Pediatr Infect Dis J; 2012 Jun; 31(6):e86-91. PubMed ID: 22466328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
    Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
    Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats.
    Planty C; Mallett CP; Yim K; Blanco JC; Boukhvalova M; March T; van der Most R; Destexhe E
    Hum Vaccin Immunother; 2017 Jan; 13(1):90-102. PubMed ID: 27629482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
    Duval X; Caplanusi A; Laurichesse H; Deplanque D; Loulergue P; Vaman T; Launay O; Gillard P
    BMC Infect Dis; 2012 Jul; 12():162. PubMed ID: 22824474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.